The Patent Finder

Terms ending in 2028

Acceleron Pharma Inc.

Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,343,933Variants Derived from Actriib and Uses Therefor
In force
 · High confidence
Acceleron Pharma, Inc.In forceHigh confidence
US 9,399,669Variants Derived from Actriib
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 10,259,861Variants Derived from Actriib and Uses Therefor
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 7,842,663Variants Derived from Actriib and Uses Therefor
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 10,093,707Antagonists of Activin-Actriia and Uses for Increasing Red Blood Cell Levels
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 8,367,611Activin-Actriia Antagonists for Inhibiting Germ Cell Maturation
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 9,353,356Activin-Actriia Antagonists for Treating a Follicle-Stimulating Hormone-Secreting Pituitary Tumor
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 8,455,428ALK1 Receptor and Ligand Antagonists and Uses Thereof
In force
 · High confidence
Acceleron Pharma, Inc.In forceHigh confidence
US 7,960,343Activin-Actriia Antagonists and Uses for Decreasing or Inhibiting FSH Secretion
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited